Childhood Obesity, Childhood Overweight, NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Pediatric Obesity
Conditions
Keywords
Non-alcoholic Fatty Liver Disease, NAFLD, NASH, Non-alcoholic Steatohepatitis, Liver inflammation, Overweight, Obesity, Adolescents, Children, Lifestyle, Combined lifestyle intervention
Brief summary
Obesity is associated with a variety of co-morbidities. Children with obesity are more likely to have risk factors associated with cardiovascular diseases (CVD) and CVD risk markers (e.g. hypertension, elevated serum cholesterol, and type 2 diabetes mellitus), but also with organ specific pathologies such as a non-alcoholic fatty liver disease (NAFLD). A recent meta-analysis has shown that the prevalence of NAFLD in obese pediatric populations is approximately 35%, compared to approximately 8% in general pediatric population, making it a very important health threat in these populations. Successful pharmacological interventions to treat or prevent NASH are not yet available and so far only weight loss has clear benefits. However, it is well known that sustained weight-loss is difficult to achieve on the longer-term. The investigators recently demonstrated in mice that plant sterol and stanol ester consumption inhibited the development of liver inflammation. Moreover, Javanmardi et al. recently demonstrated in a population of adult NAFLD patients, that plasma concentrations of Alanine Transaminase (ALT) were reduced after daily plant sterol consumption (1.6 g/d) for 6 weeks. In this study, the investigators propose to evaluate the effect of consuming soft chews enriched with plant stanol esters (3 grams/day) on ALT concentrations in children with overweight or (morbid) obesity who are at risk of developing NAFLD, in a randomized, placebo-controlled, double blinded study with an intervention period and follow-up period of 6 months. 52 overweight and obese children with elevated ALT concentrations (\>39 U/L for boys and \>33 U/L for girls) will be included. All children will be randomly allocated to consume control or plant stanol ester enriched soft chews on a daily basis for a period of 6 months. After 12 months there will be an additional blood sample to evaluate whether the 6 months intervention is still effective.
Interventions
DIETARY_SUPPLEMENTPlacebo
Oral consumption of 6 placebo chews per day for 6 months. Chews are consumed with main meals: two with breakfast, two with lunch and two with dinner.
DIETARY_SUPPLEMENTPlant stanols (3g/day)
Oral consumption of 6 plant stanol enriched chews per day for 6 months (total dosage is 3g/day). Chews are consumed with main meals: two with breakfast, two with lunch and two with dinner.
Sponsors
Maastricht University Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
4 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* Participation in lifestyle intervention, provided by the Centre for Overweight Adolescent and Children Healthcare (COACH), at the Department of Pediatrics at the Maastricht University Medical Center (MUMC+). * Age between 4-18 years old * Plasma ALT concentrations above 39 U/L for boys and above 33 U/L for girls. * Willingness to consume 6 soft chews on a daily basis, for a period of 6 months.
Exclusion criteria
* Presence of a severe medical condition, which contraindicates, in the investigators judgement, entry to the study. * No signed informed consent by relevant parties (parents of children aged below 12 years, parents and or children aged between 12 and 16 years, or children aged 16 years and older).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in plasma ALT concentration at 6 and 12 months. | Baseline, 6 months and 12 months | Plasma ALT (Alanine Aminotransferase) concentration is a laboratory parameter, measured in blood, reflecting possible presence of NAFLD. Concentrations below 26 U/L for boys, and below 22 U/L for girls, are considered normal. Concentrations above 39 U/L for boys, and above 33 U/L are considered to reflect presence of NAFLD. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in liver inflammation parameters at 6 and 12 months. | Baseline, 6 months and 12 months | Cathepsin-D and acid phosphatase are laboratory parameters, measured in mg/L in the participants blood, reflecting liver inflammation. |
| Change in lipid metabolism parameters at 6 and 12 months. | Baseline, 6 months and 12 months | Serum total cholesterol, HDL cholesterol, triacylglycerol (TAG) with correction for free glycerol and non-esterified fatty acids (NEFA) are laboratory parameters, measured in mmol/L in the participants blood, reflecting their lipid metabolism. |
| Change in lipid protein metabolism parameters at 6 and 12 months. | Baseline, 6 months and 12 months | ApoA1 and apoB100 plasma concentrations are laboratory parameters, measured in g/L in the participants blood, reflective of the lipoprotein metabolism. |
| Change in plasma glucose concentration at 6 and 12 months. | Baseline, 6 months and 12 months | Fasting glucose is a laboratory parameter, measured in mmol/L in the participants blood, reflecting glucose metabolism. |
| Change in plasma insulin concentration at 6 and 12 months. | Baseline, 6 months and 12 months | Fasting insulin concentrations is a laboratory parameters, measured in mU/L in the participants blood, reflecting glucose metabolism. |
| Change in plasma AST and plasma CK-18 concentration at 6 and 12 months. | Baseline, 6 months and 12 months | Aspartate Aminotransferase (AST) and cytokeratin-18 (CK-18) are laboratory parameters, measured in the participants blood in U/L, reflecting liver health. |
| Change in non-cholesterol sterol and oxy(phyto)sterol concentrations at 6 and 12 months. | Baseline, 6 months and 12 months | A panel of non-cholesterol sterols, as surrogate markers for cholesterol absorption and synthesis will be measured in the participants blood. |
| Change in plasma inflammatory markers at 6 and 12 months. | Baseline, 6 months and 12 months | Plasma concentrations of CRP and high sensitivity CRP will be measured in mg/L in the participants blood, to assess presence of low-grade inflammation in the body. |
| Change in ultrasonographic hepatorenal index (HRI) at 6 and 12 months. | Baseline, 6 months and 12 months | HRI is measured during a conventional ultrasound of the liver, in which three close-up images of the liver and right kidney are made by a physician-researcher. HRI is calculated from these images by a pediatric radiologist, as the ratio of the hepatic brightness and the renal brightness (HRI = echogenicity of the liver/echogenicity of the kidney). The average of the three images is taken as the definite HRI, as a reflection of hepatic fat content. |
| Change in continuous Controlled Attenuation Parameter (CAP) at 6 and 12 months. | Baseline, 6 months and 12 months | CAP is measured during a vibration controlled transient elastography of the liver, which is performed with a Fibroscan by a physician-researcher. The value is a reflection of hepatic fat content. |
| Change in insulin sensitivity at 6 and 12 months. | Baseline, 6 months and 12 months | Insulin sensitivity will be calculated using the HOMA-IR formula (homeostatis model) which is (fasting glucose\*fasting insulin) /22,5. As HOMA-IR is a ratio, it does not have a unit. |
Countries
Netherlands
Contacts
Primary ContactAnita CE Vreugdenhil, MD, PhD
Backup ContactJudith W Lubrecht, MD
Outcome results
None listed